ETH grants CovalX a Worldwide Exclusive License for the patent covering CovalX's technologies
The Swiss Federal Institute of Technology (ETH, Zürich) grants CovalX a Worldwide Exclusive License for the patent covering the analysis of protein-protein interactions by High-Mass MALDI ToF mass spectrometry.
The ETH is a science and technology university located in the city of Zürich, Switzerland and regularly ranked among the top universities in the world. The licensed technology, object of the agreement, has been developed in the group of Professor Renato Zenobi at the Department of Chemistry and Applied Biosciences.
CovalX AG is a biotechnology company located in Zürich offering a unique solution for the analysis of protein-protein interactions, protein aggregates and drug candidates based on mass spectrometry technology. CovalX’s customers are major Pharma and Biotech companies as well as academic laboratories involved in protein interactions research or protein characterization. CovalX offers dedicated chemicals, hardware and software for an easy and accurate analysis of protein complexes by MALDI ToF mass spectrometry.
“This agreement is the conclusion of several years of fruitful collaborations between CovalX and ETH in the field of mass spectrometry and non-covalent interactions. This exclusive license is also a reference for the current scientific collaborations with this Institute, developed in the frame of the KTI federal program” said Dr. Ryan Wenzel, Chief Technology Officer of the Swiss company.
The announcement of the agreement was issued from the American Society for Mass Spectrometry conference, at the Convention Center of Indianapolis, USA.
More information about CovalX and CovalX’s products on www.covalx.com